Yahoo
    HKSE - Delayed Quote HKD

    RemeGen Co., Ltd. (9995.HK)

    64.850 +1.500 (+2.37%)
    At close: October 30 at 4:08:07 PM GMT+8
    Loading Chart for 9995.HK
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Chinese and Foreign Translators and Media Figures Discuss New Drivers of Yantai's Development

    Chinese and Foreign Translators and Media Figures Discuss New Drivers of Yantai's Development
    PR Newswire 2d ago
    Chinese and Foreign Translators and Media Figures Discuss New Drivers of Yantai's Development

    Chinese and Foreign Translators and Media Figures Discuss New Drivers of Yantai's Development
    PR Newswire 2d ago
    RemeGen (SEHK:9995) Stock Looks Reasonable After Its 78% Three Year Run

    RemeGen (SEHK:9995) Stock Looks Reasonable After Its 78% Three Year Run
    Simply Wall St. 11d ago
    Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis

    Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis
    GlobeNewswire 1mo ago
    Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

    Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
    GlobeNewswire 4mo ago
    Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

    Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
    GlobeNewswire 5mo ago
    Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

    Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
    GlobeNewswire 8d ago
    Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

    Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
    GlobeNewswire 4mo ago
    Asian Market Picks: Mao Geping Cosmetics And 2 Other Stocks That May Be Priced Below Their Estimated Value

    Asian Market Picks: Mao Geping Cosmetics And 2 Other Stocks That May Be Priced Below Their Estimated Value
    Simply Wall St. 8mo ago
    Asian Market Value Picks Featuring 3 Stocks Trading Below Estimated Worth

    Asian Market Value Picks Featuring 3 Stocks Trading Below Estimated Worth
    Simply Wall St. 10mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: